Physician profile
Foluke Uche
NPI 1841472438
$2,746.33
in general payments reported to CMS, 2019-2025
24 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.99 · 2020: $63.83 · 2021: $358 · 2022: $671 · 2023: $395 · 2024: $700 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $463.97 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $420.38 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $298.19 | 2022-2025 | Mounjaro, Zepbound, Reyvow |
| Novo Nordisk INC | $266.38 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $203.61 | 2020-2022 | |
| Exact Sciences Corporation | $151.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $151.12 | 2021-2025 | Arexvy, Shingrix |
| Amgen INC. | $135.52 | 2022-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.61 | 2019-2022 | |
| Incyte Corporation | $124.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $116.94 | 2021-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $67.89 | 2022 | |
| Boston Scientific Corporation | $27.97 | 2020-2025 | General - Pain Management |
| Bayer Healthcare Pharmaceuticals INC. | $26.44 | 2023 | |
| Arbor Pharmaceuticals, INC. | $24.08 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21.22 | 2021 | |
| Itamar Medical INC | $17.17 | 2024 | Watchpatone |
| Dexcom, INC. | $17.15 | 2024 | Dexcom G6 Transmitter |
| Inogen, INC. | $16.50 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Nevro Corp. | $16.30 | 2023 | Senza |
| Alexion Pharmaceuticals, INC. | $14.55 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $12.97 | 2019 | |
| Mylan Institutional INC. | $12.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Foluke Uche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.